Brief: Syndax And Incyte Announce Positive Topline Results From The Pivotal AGAVE-201 Trial Of Axatilimab In Chronic Graft-Versus-Host Disease

Syndax Pharmaceuticals

24/07/2023 12:37

July 24 (Reuters) - Incyte Corp  INCY.O :
    * SYNDAX AND INCYTE ANNOUNCE POSITIVE TOPLINE RESULTS FROM
THE
PIVOTAL AGAVE-201 TRIAL OF AXATILIMAB IN CHRONIC
GRAFT-VERSUS-HOST DISEASE
    * INCYTE CORP - TRIAL MET PRIMARY ENDPOINT ACROSS ALL
COHORTS WITH
OVERALL RESPONSE RATE OF 74% AT A DOSE OF 0.3 MG/KG ADMINISTERED
EVERY TWO WEEKS
    * INCYTE CORP - DATA HIGHLIGHT DURABLE RESPONSE TO TREATMENT
    * INCYTE CORP - AT 0.3 MG/KG DOSE, 60% OF PATIENTS WHO
RESPONDED
TO AXATILIMAB WERE STILL RESPONDING AT ONE YEAR
    * INCYTE CORP - SYNDAX AND INCYTE INTEND TO FILE A BIOLOGICS
LICENSE APPLICATION (BLA) BY YEAR-END 2023

Source text for Eikon:  ID:nPn1DQtNBa 
Further company coverage:  INCY.O 

 ((Reuters.Briefs@thomsonreuters.com;))